Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors

Pazopanib is US FDA approved for the treatment of advanced soft tissue sarcomas. All patients with this disease ultimately develop resistance to therapy. Mechanisms of resistance include activation of the mTOR, histone deacetylase (HDAC), MAPK, and ERBB4 pathways. We hypothesized that combining pazo...

Full description

Saved in:
Bibliographic Details
Published in:Sci Rep
Main Authors: Dembla, Vikas, Groisberg, Roman, Hess, Ken, Fu, Siqing, Wheler, Jennifer, Hong, David S., Janku, Filip, Zinner, Ralph, Piha-Paul, Sarina Anne, Ravi, Vinod, Benjamin, Robert S., Patel, Shreyaskumar, Somaiah, Neeta, Herzog, Cynthia E., Karp, Daniel D., Roszik, Jason, Meric-Bernstam, Funda, Subbiah, Vivek
Format: Artigo
Language:Inglês
Published: Nature Publishing Group UK 2017
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5698336/
https://ncbi.nlm.nih.gov/pubmed/29162825
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-13114-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items